Maintaining a good glycemic control is crucial in the management of diabetes mellitus (DM) as it is associated with the reduction in both macro and microvascular complications of the disease. Self-monitoring of blood glucose (SMBG), which provides the day-today blood glucose levels, is a simple and practical tool for maintaining a good glycemic control. Although SMBG is widely practiced in other countries, its use in India is very limited. Even when used, it is not carried out is a structured manner. There seems to be a lack of education about the purpose of SMBG and the correct process and schedule to be followed. This highlights the unmet need for country-specific SMBG recommendations. In order to fulfil this need, a panel of expert endocrinologists/ diabetologists came together under the aegis of Research Society for the Study of Diabetes in India (RSSDI). They reviewed the current literature, combined the evidences with their clinical knowledge and expertise, and developed consensus recommendations for SMBG practice in India. This document provides a comprehensive review of the current literature on SMBG and presents the recommendations made by the expert panel.

No abstract

No abstract

Introduction: Teneligliptin is an antidiabetic medication that has been approved for the management of type 2 diabetes mellitus (T2DM) in Japan, South Korea and India. It is one of the most commonly prescribed antihyperglycaemic agents. The aim of this study was to assess the effectiveness of teneligliptin in improving glycemic control amongst Indian patients with T2DM in a real-world setting. Methods: This was a retrospective observational study in which a predesigned structured proforma was used to collect information from hospital records of 18 medical centres across India. All participating centres were established primary care hospitals with adequate record keeping, a predetermined condition in the study design. Data were collected during the period of January 2019 to June 2019. Data extracted from patient records, including glycaemic parameters, concomitant drugs, drug dosage and duration, were collated. The effectiveness of teneligliptin was assessed by analyzing the mean change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) at 12 weeks after initiation of teneligliptin. Results: Data from 10,623 patients were available for analysis. The mean age of the enrolled patients was 51.86 ± 11.76 years. At 12 weeks after initiation of teneligliptin as monotherapy or add-on to other medications (combination therapy), the patients showed a signficant decrease from baseline in mean HbA1c, FPG and PPG. Mean HbA1c dropped from 8.66 ± 1.

Background: Teneligliptin is been introduced recently in Indian market and data available are limited on Indian patients. Hence, the hospital based real life retrospective evaluation was planned out to evaluate, the efficacy of teneligliptin in type 2 diabetes mellitus in Indian population. Hence study was designed, a retrospective evaluation, of efficacy of teneligliptin in type 2 diabetes mellitus in Indian population.Methods: Data of 775 patients, who were prescribed teneligliptin was collected from hospital records. Teneligliptin 20mg was prescribed to all patients who were uncontrolled on other OHAs and for a mean duration of 8 weeks. Parameter evaluated in this study were change in FBG, PPBG and HbA1c from the baseline at 8week. With profile of outcome i.e. response and failure rates were also assessed with respect to age, gender, BMI and duration of diabetes.Results: Of 775 patients were enrolled, 427 were males and 348 females. The average age was 53.04 years among the study population. The mean duration of diabetes was 23 months. There was significant change in HbA1c, fasting and postprandial blood glucose levels at 8 week of teneligliptin therapy. Changes in HbA1c, FPG and PPG from baseline to end of study were-1.22±1.12% (p=0.001), -35.8±25.5mg/dl (p=0.001) and -60.7±28.6mg/dl (p=0.001) respectively. Out of 775 patients, 106 (13,7%) were non-responders where it was further sub analysed with different parameter such as age, gender, BMI and duration of diabetes in order to observe response of teneligliptin in diabetic patients.Conclusions: This real life retrospective evaluation showed efficacy of teneligliptin in real world scenario. It can be an effective alternative to conventional gliptins available for prescription in India.